Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has successfully secured a $110 million Series E financing led...
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico...
The research demonstrates a breakthrough in applying quantum-enhanced generative AI to drug discovery using today’s quantum devices.
Zapata Computing, Inc., the Industrial Generative AI company,...